Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function

0571307 - FZÚ 2024 RIV NL eng J - Článek v odborném periodiku
Uzhytchak, Mariia - Smolková, Barbora - Lunova, Mariia - Frtús, Adam - Jirsa, M. - Dejneka, Alexandr - Lunov, Oleg
Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function.
Advanced Drug Delivery Reviews. Roč. 197, June (2023), č. článku 114828. ISSN 0169-409X. E-ISSN 1872-8294
Grant CEP: GA MŠMT(CZ) EF16_019/0000760
Grant ostatní: OP VVV - SOLID21(XE) CZ.02.1.01/0.0/0.0/16_019/0000760
Institucionální podpora: RVO:68378271
Klíčová slova: nanomedicines * nanoparticles * drug-induced liver injury (DILI) * endocytosis * cytotoxicity * lysosomes * apoptosis * autophagy * cancer * nanotoxicity
Obor OECD: Biophysics
Impakt faktor: 16.1, rok: 2022
Způsob publikování: Omezený přístup
http://doi.org/10.1016/j.addr.2023.114828

Although several nanomedicines got clinical approval over the past two decades, the clinical translation rate is relatively small so far. There are many post-surveillance withdrawals of nanomedicines caused by various safety issues. For successful clinical advancement of nanotechnology, it is of unmet need to realize cellular and molecular foundation of nanotoxicity. Current data suggest that lysosomal dysfunction caused by nanoparticles is emerging as the most common intracellular trigger of nanotoxicity. This review analyzes prospect mechanisms of lysosomal dysfunction-mediated toxicity induced by nanoparticles. We summarized and critically assessed adverse drug reactions of current clinically approved nanomedicines.
Trvalý link: https://hdl.handle.net/11104/0342561